- Home
- SMHI vs SLS Comparison
SMHI vs SLS Comparison
Compare SMHI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMHI
- SLS
- Stock Information
- Founded
- SMHI 1989
- SLS 2012
- Country
- SMHI United States
- SLS United States
- Employees
- SMHI N/A
- SLS N/A
- Industry
- SMHI Marine Transportation
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- SMHI Consumer Discretionary
- SLS Health Care
- Exchange
- SMHI Nasdaq
- SLS Nasdaq
- Market Cap
- SMHI 150.4M
- SLS 165.6M
- IPO Year
- SMHI N/A
- SLS N/A
- Fundamental
- Price
- SMHI $6.43
- SLS $1.58
- Analyst Decision
- SMHI
- SLS Strong Buy
- Analyst Count
- SMHI 0
- SLS 1
- Target Price
- SMHI N/A
- SLS $7.00
- AVG Volume (30 Days)
- SMHI 108.2K
- SLS 2.3M
- Earning Date
- SMHI 07-30-2025
- SLS 08-19-2025
- Dividend Yield
- SMHI N/A
- SLS N/A
- EPS Growth
- SMHI N/A
- SLS N/A
- EPS
- SMHI N/A
- SLS N/A
- Revenue
- SMHI $255,033,000.00
- SLS N/A
- Revenue This Year
- SMHI N/A
- SLS N/A
- Revenue Next Year
- SMHI $11.59
- SLS N/A
- P/E Ratio
- SMHI N/A
- SLS N/A
- Revenue Growth
- SMHI N/A
- SLS N/A
- 52 Week Low
- SMHI $3.63
- SLS $0.77
- 52 Week High
- SMHI $11.67
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- SMHI 63.98
- SLS 38.26
- Support Level
- SMHI $4.70
- SLS $1.56
- Resistance Level
- SMHI $6.84
- SLS $1.71
- Average True Range (ATR)
- SMHI 0.34
- SLS 0.10
- MACD
- SMHI 0.13
- SLS -0.02
- Stochastic Oscillator
- SMHI 80.89
- SLS 5.00
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.